MX2015007126A - Piridopirazinas sustituidas como inhibidores de syk. - Google Patents

Piridopirazinas sustituidas como inhibidores de syk.

Info

Publication number
MX2015007126A
MX2015007126A MX2015007126A MX2015007126A MX2015007126A MX 2015007126 A MX2015007126 A MX 2015007126A MX 2015007126 A MX2015007126 A MX 2015007126A MX 2015007126 A MX2015007126 A MX 2015007126A MX 2015007126 A MX2015007126 A MX 2015007126A
Authority
MX
Mexico
Prior art keywords
syk inhibitors
pyridopyrazines
substituted
substituted pyridopyrazines
syk
Prior art date
Application number
MX2015007126A
Other languages
English (en)
Inventor
Wei Deng
Wei-Guo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50882786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015007126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2015007126A publication Critical patent/MX2015007126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a compuestos de piridopirazina de fórmula (I), las composiciones farmacéuticas de los mismos y por lo tanto métodos de uso, en donde R1, R2, R3, L, m, p y W son como se definen en la especificación. (ver Fórmula).
MX2015007126A 2012-12-07 2013-12-06 Piridopirazinas sustituidas como inhibidores de syk. MX2015007126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/086144 WO2014086032A1 (en) 2012-12-07 2012-12-07 Substituted pyridopyrazines as syk inhibitors
PCT/CN2013/088817 WO2014086316A1 (en) 2012-12-07 2013-12-06 Substituted pyridopyrazines as syk inhibitors

Publications (1)

Publication Number Publication Date
MX2015007126A true MX2015007126A (es) 2015-10-14

Family

ID=50882786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007126A MX2015007126A (es) 2012-12-07 2013-12-06 Piridopirazinas sustituidas como inhibidores de syk.

Country Status (17)

Country Link
US (2) US20150307491A1 (es)
EP (1) EP2928888A4 (es)
JP (1) JP6105745B2 (es)
KR (1) KR20150091169A (es)
AU (1) AU2013354552B2 (es)
BR (1) BR112015012825A2 (es)
CA (1) CA2891725A1 (es)
CL (1) CL2015001516A1 (es)
EA (1) EA201590787A1 (es)
HK (1) HK1210178A1 (es)
IL (1) IL239153A0 (es)
MX (1) MX2015007126A (es)
PE (1) PE20151145A1 (es)
PH (1) PH12015501175A1 (es)
SG (1) SG11201503848UA (es)
TW (1) TW201422616A (es)
WO (2) WO2014086032A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251565B2 (en) * 2015-04-30 2019-04-09 Dna Medicine Institute, Inc. Multi-channel vitals device
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US11464460B2 (en) 2019-10-21 2022-10-11 Pratyush Pavan Devarasetty Systems, devices, and methods for detecting physical distress in infant tracheostomy patients
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20230000871A1 (en) 2019-11-08 2023-01-05 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023193054A1 (en) * 2022-04-07 2023-10-12 Uniquest Pty Ltd Spleen tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115479A (zh) * 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8604049B2 (en) * 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
EP2324022A1 (de) * 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
CN102574847A (zh) * 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
NZ600857A (en) * 2010-01-29 2014-06-27 Boehringer Ingelheim Int Substituted naphthyridines and their use as syk kinase inhibitors
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors

Also Published As

Publication number Publication date
EP2928888A1 (en) 2015-10-14
US20150307491A1 (en) 2015-10-29
EP2928888A4 (en) 2016-04-20
HK1210178A1 (en) 2016-04-15
CA2891725A1 (en) 2014-06-12
WO2014086032A1 (en) 2014-06-12
KR20150091169A (ko) 2015-08-07
IL239153A0 (en) 2015-07-30
WO2014086316A1 (en) 2014-06-12
AU2013354552A1 (en) 2015-07-23
CL2015001516A1 (es) 2015-10-23
BR112015012825A2 (pt) 2017-07-11
JP2016501237A (ja) 2016-01-18
SG11201503848UA (en) 2015-06-29
US20170152258A9 (en) 2017-06-01
AU2013354552B2 (en) 2016-09-29
US20160002221A1 (en) 2016-01-07
JP6105745B2 (ja) 2017-03-29
PH12015501175A1 (en) 2015-08-17
TW201422616A (zh) 2014-06-16
EA201590787A1 (ru) 2015-11-30
PE20151145A1 (es) 2015-08-03

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
IN2014MN02598A (es)
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
IN2014CN04530A (es)
PH12015501083B1 (en) Novel pyridine derivatives
PH12015501609A1 (en) Phenicol antibacterials
PH12015501038A1 (en) Inhibitors of iap
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
IN2014DN09314A (es)
IN2015DN00950A (es)
MX342960B (es) Derivados de cromeno.
IN2015DN02109A (es)
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.